When must pharmacokinetic (PK) impact studies be available?

• A. Prior to use of the new formulation in clinical trials
• B. After the new formulation is used in clinical trials
• C. Only if requested by regulators
• D. Never

Answer: (A)

Evaluating how a new formulation behaves in the body is essential before starting human trials. Pharmacokinetic impact studies show whether the reformulated product changes absorption, distribution, metabolism, or excretion enough to alter overall exposure. Having this data beforehand helps ensure appropriate dose selection, safety monitoring, and that any needed bridging or regulatory steps are addressed early.

If PK differences were discovered only after trials began, participants could be exposed to unexpected drug levels, which could affect safety or efficacy and complicate study results. That’s why regulators and good clinical practice emphasize having PK information available before the new formulation is used in clinical studies.

The other options don’t fit because PK data are typically needed as part of the development plan rather than only on regulator request, and they aren’t something you skip until after trials—or never needed.